Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

China Surprises With First CRISPR Trial Despite Regulatory Lag, Concerns

Executive Summary

The lack of a comprehensive regulatory pathway has not hindered Chinese researchers from forging ahead with the world's first human clinical study using CRISPR-Cas9 gene editing technology, which will be used to treat advanced lung cancer.

Advertisement

Related Content

Innovative ‘Quick Followers’ Grabbing China Investment
2016 Review: Rapid Change Defines China Regulatory Environment
Scrip's Rough Guide To CRISPR Gene Editing
SAD, BAD Or DAD? Insiders See Risks Increasing In China IO Rush

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register